May is #MentalHealthMonth . In recognition of @mentalhealtham's theme of #LookAroundLookWithin , we're reflecting on how nature and nurture both play a role in #mentalhealth : hubs.li/Q01N8S2b0

Next week, our CEO and Founder Nawal Roy will speak at the Future of Mental Healthcare Summit about state-of-the-art innovations in behavioral health measurement--and how those innovations drive improved outcomes. #mentalhealth #RWD Learn more or register: hubs.li/Q01L1mJD0

Excited that our Founder and CEO Nawal Roy had the chance to share his insights in this report from Digital Health New York! Check out the report below, or read more of his thoughts about reducing #mentalhealth stigma on the blog: info.holmusk.com/blog/how-dhnys…

New publication: An analysis of #RWD from our #NeuroBlu Database explores a question that has been investigated in several #cllinicaltrials about a treatment for major depressive disorder. Do findings from routine care reflect the study setting? Find out: hubs.li/Q01KbLrQ0

At #EPA2023 , we presented research on clinical instability, enabled by #RWD within our #NeuroBlu Database and led by @uniofoxford senior research fellow & Holmusk collaborator @maximetaquet.
The study was also published in @thelancetpsych:
hubs.li/Q01Jp_QW0

Get the breakdown on latest #NeuroBlu -enabled research published in @TheLancetPsych from lead author Maxime Taquet! #RWE

Or read more here: holmusk.com/news/lancet-ps…

New in The Lancet Psychiatry: Analysis of #RWD from our #NeuroBlu Database, led by Maxime Taquet, shows that instability is consistently an important predictor of psychiatric hospitalization risk across diagnoses, ages, & sex: hubs.li/Q01JlHxG0

Our Founder and CEO, Nawal Roy, reflects on the recently announced strategic investment from Veradigm® and what this means for Holmusk's future: info.holmusk.com/blog/new-year-…
#RWE #behavioralhealth

Exciting news! Veradigm® has invested in Holmusk, leading their $45 million Series B fundraising round. Holmusk will leverage this investment to continue its rapid expansion of its flagship offering, the NeuroBlu Database ➡️ bit.ly/3iqU71c

Look out for even more exciting work from Holmusk following this impressive series B fundraising round led by Veradigm®. The time to invest in mental health is now!

We are delighted to share that Veradigm® has invested in Holmusk, leading our $45 million Series B fundraising round. We look forward to continuing our work in building a leading #RWD source to advance research and care for behavioral health conditions.

Thanks to Duke-Margolis' RWE Collaborative for inviting us to speak to fellow members during a two-day workshop on patient subgroups! Read more about why #RWE is needed to find the best treatment for everyone: info.holmusk.com/blog/one-treat…

Thanks to CNWL NHS FT for having us to their Psychiatrist Conference in London today! We were pleased to share how #MaST has been implemented within their CMHTs and share more information about speciality modules within the tool. Learn more about MaST: holmusk.co.uk

We are also attending @NIHRResearch's MedTech 2022 to share findings on how our clinical decision support tool, #MaST , has impacted #mentalhealth care delivery within Mersey Care NHS FT 🏳️‍🌈. Read more: hubs.li/Q01t53x00

We're honored to present two posters at #DGPPN2022 , using #RWD from our #NeuroBlu database to gain new insights on #mentalhealth after the #COVID19 pandemic, as well as positive and negative symptoms in patients with #schizophrenia . See the posters: hubs.li/Q01t78s10

Also at #CNSSummit2022 , our Chief Medical Officer Scott Kollins will be moderating an expert panel on #RWE for behavioral health. Looking forward to hearing from experts from Boehringer Ingelheim, Health Advances, Revesight Consulting, @pluto_health, @otsukaus, and People with Empathy.

We're looking forward to CNS Summit this weekend! On Saturday, our Chief Medical Officer, @skollins1, Scott Kollins, will give a Neuroscience Spotlight presentation on the work we're doing to advance #RWE for behavioral health. See the agenda: hubs.li/Q01ss09d0

#CNSSummit2022

Looking forward to #ADHD 2022 and tomorrow's keynote from our Chief Medical Officer, @skollins1, Scott Kollins! He will be discussing how the use of #RWD in #clinicalresearch is impacting care for patients with #ADHD . Register here: lnkd.in/gss3K7X5 CHADD

How is our #NeuroBlu data different than other sources of EHR-derived #RWD ? In this blog, we explore the coverage and representativeness of the NeuroBlu Database. Read more: hubs.li/Q01slq-80

Looking forward to #CNSSummit2022 next week, where our Chief Medical Officer @skollins1, Scott Kollins will be moderating an amazing panel of speakers who will be discussing #RWE in behavioral health!